Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 28, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 300,000 ordinary shares.
- Price per Share: 1,177.11 pence.
- Total Voting Rights (Excluding Treasury): 5,217,254,004 shares.
- Treasury Shares Held: 474,194,158 shares (representing 9.09% of total voting rights).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 300,000 repurchased shares. Consequently, the number of shares held in Treasury increased to 474,194,158. The filing does not report material changes in operating performance or financial position compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Checklist
- Verify the total number of shares in issue (5,217,254,004) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on the total voting rights percentage (9.09%).
- Note that this filing does not contain earnings data; refer to Form 20-F or quarterly reports for financial performance metrics.